March 8, 2011Journal of Clinical OncologyOpen Access

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

View Full Paper

Ask AI

Bookmark

Abstract

Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grunberg et al. (2011) studied this question.

synapsesocial.com/papers/69d75103ef4aa71f97f30bc2 https://doi.org/10.1200/jco.2010.31.7859

View Full Paper

Ask AI

Bookmark

Abstract

Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Abstract

Discussion

Cite This Study

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Abstract

Discussion

Cite This Study

Keep reading

Keep reading